[Comment] The unexpected success of NRTIs in second-line treatment

Genotype-defined resistance to antiretrovirals supposedly predicts future virological failure. Findings from clinical studies, including the 144 week results from the EARNEST trial, published in The Lancet Infectious Diseases,1 challenge this decades-long dogma, certainly when it comes to nucleoside analogues.

Source: The Lancet Infectious Diseases - November 4, 2017 Category: Infectious Diseases Authors: Andrew M Hill, Francois Venter Tags: Comment Source Type: research